Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last kr114.80 SEK
Change Today +3.30 / 2.96%
Volume 598.7K
SOBI On Other Exchanges
Symbol
Exchange
Stockholm
Berlin
OTC US
OTC US
As of 11:29 AM 07/29/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Cameron Geoffrey McDonough M.D.

Chief Executive Officer and President, Swedish Orphan Biovitrum AB
AgeTotal Calculated CompensationThis person is connected to 13 board members in 1 different organizations across 3 different industries.

See Board Relationships
45kr12,213,000
As of Fiscal Year 2014

Background*

Dr. Cameron Geoffrey McDonough, also known as Geoff, has been the Chief Executive Officer and President at Swedish Orphan Biovitrum AB since August 15, 2011. Dr. McDonough has been with Sobi since August 2011. He also held several senior leadership positions at Genzyme Corporation from 2002 to 2011 including as its President of Organization in Europe since May 2010 and demonstrated strong leadership of its Personalized Genetic Health business during a challenging period. ...

Read Full Background

Corporate Headquarters*

Tomtebodavägen 23A
Stockholm, Stockholm County 112 76

Sweden

Phone: 46 86 97 20 00
Fax: 46 86 97 23 30

Board Members Memberships*

2012-Present
Director

Education*

MD
Harvard Medical School
BA
University of North Carolina
BS
University of North Carolina

Other Affiliations*

Annual Compensation*

Salarykr3,614,000
Bonuskr1,803,000
Total Annual Compensationkr5,417,000

Stock Options*

All Other Compensationkr6,796,000

Total Compensation*

Total Annual Cash Compensationkr12,213,000
Total Short Term Compensationkr5,417,000
Other Long Term Compensationkr6,796,000
Total Calculated Compensationkr12,213,000
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SOBI:SS kr114.80 SEK +3.30

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
John Dawson Chief Executive Officer and Executive Director
Oxford BioMedica PLC
641.0K GBP
Edwin Moses Ph.D.Chief Executive Officer, Director and Member of Research & Development Committee
Ablynx NV
--
William J. Polvino M.D.Chief Executive Officer and President
Veloxis Pharmaceuticals A/S
--
Compensation as of Fiscal Year 2014.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SWEDISH ORPHAN BIOVITRUM AB, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.